Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy

ACS Chemical Biology

Volumn 12, Issue 4, 2017, Pages 892-898

  Ottis, Philipp ^a   Crews, Craig M ^a,b  

^a Cellular and Developmental Biology ^*  (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBLON; DRUG; INHIBITOR OF APOPTOSIS PROTEIN 1; LIGAND; METHIONYL AMINOPEPTIDASE 2; PEPTIDE; PROTEIN; PROTEIN BRD4; PROTEIN MDM2; PROTEOLYSIS TARGETING CHIMERA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; MOLECULAR LIBRARY;

DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY;

DRUG DESIGN; HUMANS; PROTEINS; PROTEOLYSIS; SMALL MOLECULE LIBRARIES;

EID: 85018502363     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.6b01068     Document Type: Review

References (45)

1. Paik, Y.-K., Jeong, S.-K., Omenn, G. S., Uhlen, M., Hanash, S., Cho, S. Y., Lee, H.-J., Na, K., Choi, E.-Y., Yan, F., Zhang, F., Zhang, Y., Snyder, M., Cheng, Y., Chen, R., Marko-Varga, G., Deutsch, E. W., Kim, H., Kwon, J.-Y., Aebersold, R., Bairoch, A., Taylor, A. D., Kim, K. Y., Lee, E.-Y., Hochstrasser, D., Legrain, P., and Hancock, W. S. (2012) The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome Nat. Biotechnol. 30, 221-223 10.1038/nbt.2152
2. Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., and Woolsey, J. (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration Nucleic Acids Res. 34, D668-D672 10.1093/nar/gkj067
3. Fedorov, Y., Anderson, E. M., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K., Leake, D., Marshall, W. S., and Khvorova, A. (2006) Off-target effects by siRNA can induce toxic phenotype RNA 12, 1188-1196 10.1261/rna.28106
4. Burnett, J. C. and Rossi, J. J. (2012) RNA-based therapeutics: current progress and future prospects Chem. Biol. 19, 60-71 10.1016/j.chembiol.2011.12.008
5. Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., and Deshaies, R. J. (2001) Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation Proc. Natl. Acad. Sci. U. S. A. 98, 8554-8559 10.1073/pnas.141230798
6. Sakamoto, K. M., Kim, K. B., Verma, R., Ransick, A., Stein, B., Crews, C. M., and Deshaies, R. J. (2003) Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation Mol. Cell. Proteomics 2, 1350-1358 10.1074/mcp.T300009-MCP200
7. Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., and Kaelin, W. G. (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein Nat. Cell Biol. 2, 423-427 10.1038/35017054
8. Tanimoto, K., Makino, Y., Pereira, T., and Poellinger, L. (2000) Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein EMBO J. 19, 4298-4309 10.1093/emboj/19.16.4298
9. Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., Tian, Y.-M., Masson, N., Hamilton, D. L., Jaakkola, P., Barstead, R., Hodgkin, J., Maxwell, P. H., Pugh, C. W., Schofield, C. J., and Ratcliffe, P. J. (2001) C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation Cell 107, 43-54 10.1016/S0092-8674(01)00507-4
10. Schneekloth, J. S., Jr., Fonseca, F. N., Koldobskiy, M., Mandal, A., Deshaies, R., Sakamoto, K., and Crews, C. M. (2004) Chemical genetic control of protein levels: selective in vivo targeted degradation J. Am. Chem. Soc. 126, 3748-3754 10.1021/ja039025z
11. Zhang, D., Baek, S. H., Ho, A., and Kim, K. (2004) Degradation of target protein in living cells by small-molecule proteolysis inducer Bioorg. Med. Chem. Lett. 14, 645-648 10.1016/j.bmcl.2003.11.042
12. Bargagna-Mohan, P., Baek, S.-H., Lee, H., Kim, K., and Mohan, R. (2005) Use of PROTACS as molecular probes of angiogenesis Bioorg. Med. Chem. Lett. 15, 2724-2727 10.1016/j.bmcl.2005.04.008
13. Lee, H., Puppala, D., Choi, E. Y., Swanson, H., and Kim, K. B. (2007) Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool ChemBioChem 8, 2058-2062 10.1002/cbic.200700438
14. Puppala, D., Lee, H., Kim, K. B., and Swanson, H. I. (2008) Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention Mol. Pharmacol. 73, 1064-1071 10.1124/mol.107.040840
15. Cyrus, K., Wehenkel, M., Choi, E. Y., Lee, H., Swanson, H., and Kim, K. B. (2010) Jostling for Position: Optimizing Linker Location in the Design of Estrogen Receptor-Targeting PROTACs ChemMedChem 5, 979-985 10.1002/cmdc.201000146
16. Hines, J., Gough, J. D., Corson, T. W., and Crews, C. M. (2013) Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs Proc. Natl. Acad. Sci. U. S. A. 110, 8942-8947 10.1073/pnas.1217206110
17. Montrose, K. and Krissansen, G. W. (2014) Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus Biochem. Biophys. Res. Commun. 453, 735-740 10.1016/j.bbrc.2014.10.006
18. Chu, T.-T., Gao, N., Li, Q.-Q., Chen, P.-G., Yang, X.-F., Chen, Y.-X., Zhao, Y.-F., and Li, Y.-M. (2016) Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation Cell Chem. Biol. 23, 453-461 10.1016/j.chembiol.2016.02.016
19. Henning, R. K., Varghese, J. O., Das, S., Nag, A., Tang, G., Tang, K., Sutherland, A. M., and Heath, J. R. (2016) Degradation of Akt using protein-catalyzed capture agents J. Pept. Sci. 22, 196-200 10.1002/psc.2858
20. Bauer, P. O., Goswami, A., Wong, H. K., Okuno, M., Kurosawa, M., Yamada, M., Miyazaki, H., Matsumoto, G., Kino, Y., Nagai, Y., and Nukina, N. (2010) Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein Nat. Biotechnol. 28, 256-263 10.1038/nbt.1608
21. Fan, X., Jin, W. Y., Lu, J., Wang, J., and Wang, Y. T. (2014) Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation Nat. Neurosci. 17, 471-480 10.1038/nn.3637
22. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., and Liu, E. A. (2004) In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 Science 303, 844-848 10.1126/science.1092472
23. Schneekloth, A. R., Pucheault, M., Tae, H. S., and Crews, C. M. (2008) Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics Bioorg. Med. Chem. Lett. 18, 5904-5908 10.1016/j.bmcl.2008.07.114
24. Suda, H., TAKITA, T., AOYAGI, T., and UMEZAWA, H. (1976) The structure of bestatin J. Antibiot. 29, 100-101 10.7164/antibiotics.29.100
25. Itoh, Y., Ishikawa, M., Naito, M., and Hashimoto, Y. (2010) Protein Knockdown Using Methyl Bestatin-Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins J. Am. Chem. Soc. 132, 5820-5826 10.1021/ja100691p
26. Itoh, Y., Kitaguchi, R., Ishikawa, M., Naito, M., and Hashimoto, Y. (2011) Design, synthesis and biological evaluation of nuclear receptor-degradation inducers Bioorg. Med. Chem. 19, 6768-6778 10.1016/j.bmc.2011.09.041
27. Okuhira, K., Ohoka, N., Sai, K., Nishimaki-Mogami, T., Itoh, Y., Ishikawa, M., Hashimoto, Y., and Naito, M. (2011) Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein FEBS Lett. 585, 1147-1152 10.1016/j.febslet.2011.03.019
28. Demizu, Y., Okuhira, K., Motoi, H., Ohno, A., Shoda, T., Fukuhara, K., Okuda, H., Naito, M., and Kurihara, M. (2012) Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy Bioorg. Med. Chem. Lett. 22, 1793-1796 10.1016/j.bmcl.2011.11.086
29. Ohoka, N., Nagai, K., Hattori, T., Okuhira, K., Shibata, N., Cho, N., and Naito, M. (2014) Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway Cell Death Dis. 5, e1513 10.1038/cddis.2014.471
30. Sekine, K., Takubo, K., Kikuchi, R., Nishimoto, M., Kitagawa, M., Abe, F., Nishikawa, K., Tsuruo, T., and Naito, M. (2008) Small molecules destabilize cIAP1 by activating auto-ubiquitylation J. Biol. Chem. 283, 8961-8968 10.1074/jbc.M709525200
31. Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., Riley, M., Delker, S. L., Ito, T., Ando, H., Mori, T., Hirano, Y., Handa, H., Hakoshima, T., Daniel, T. O., and Cathers, B. E. (2014) Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs Nat. Struct. Mol. Biol. 21, 803-809 10.1038/nsmb.2874
32. Fischer, E. S., Bohm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., Tichkule, R. B., Schebesta, M., Forrester, W. C., Schirle, M., Hassiepen, U., Ottl, J., Hild, M., Beckwith, R. E. J., Harper, J. W., Jenkins, J. L., and Thoma, N. H. (2014) Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide Nature 512, 49-53 10.1038/nature13527
33. Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., Ciarlo, C., Hartman, E., Munshi, N., Schenone, M., Schreiber, S. L., Carr, S. A., and Ebert, B. L. (2014) Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells Science 343, 301-305 10.1126/science.1244851
34. Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., and Kaelin, W. G. (2014) The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins Science 343, 305-309 10.1126/science.1244917
35. Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., and Crews, C. M. (2015) Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4 Chem. Biol. 22, 755-763 10.1016/j.chembiol.2015.05.009
36. Bondeson, D. P., Mares, A., Smith, I. E., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., Zinn, N., Grandi, P., Shimamura, S., Bergamini, G., Faelth-Savitski, M., Bantscheff, M., Cox, C., Gordon, D. A., Willard, R. R., Flanagan, J. J., Casillas, L. N., Votta, B. J., den Besten, W., Famm, K., Kruidenier, L., Carter, P. S., Harling, J. D., Churcher, I., and Crews, C. M. (2015) Catalytic in vivo protein knockdown by small-molecule PROTACs Nat. Chem. Biol. 11, 611-617 10.1038/nchembio.1858
37. Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., and Bradner, J. E. (2015) DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation Science 348, 1376-1381 10.1126/science.aab1433
38. Lepper, E. R., Smith, N. F., Cox, M. C., Scripture, C. D., and Figg, W. D. (2006) Thalidomide metabolism and hydrolysis: mechanisms and implications Curr. Drug Metab. 7, 677-685 10.2174/138920006778017777
39. Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime-Figueroa, S., Ko, E., Hines, J., and Crews, C. M. (2016) Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL Angew. Chem., Int. Ed. 55, 807-810 10.1002/anie.201507634
40. Zengerle, M., Chan, K.-H., and Ciulli, A. (2015) Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4 ACS Chem. Biol. 10, 1770-1777 10.1021/acschembio.5b00216
41. Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M., Wang, J., Chen, X., Dong, H., Siu, K., Winkler, J. D., Crew, A. P., Crews, C. M., and Coleman, K. G. (2016) PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer Proc. Natl. Acad. Sci. U. S. A. 113, 7124-7129 10.1073/pnas.1521738113
42. Buckley, D. L., Gustafson, J. L., Van Molle, I., Roth, A. G., Tae, H. S., Gareiss, P. C., Jorgensen, W. L., Ciulli, A., and Crews, C. M. (2012) Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1alpha Angew. Chem., Int. Ed. 51, 11463-11467 10.1002/anie.201206231
43. Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., and Crews, C. M. (2012) Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1alpha interaction J. Am. Chem. Soc. 134, 4465-4468 10.1021/ja209924v
44. Van Molle, I., Thomann, A., Buckley, D. L., So, E. C., Lang, S., Crews, C. M., and Ciulli, A. (2012) Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1alpha protein-protein interface Chem. Biol. 19, 1300-1312 10.1016/j.chembiol.2012.08.015
45. Galdeano, C., Gadd, M. S., Soares, P., Scaffidi, S., Van Molle, I., Birced, I., Hewitt, S., Dias, D. M., and Ciulli, A. (2014) Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities J. Med. Chem. 57, 8657-8663 10.1021/jm5011258